Short-Term Debt to Equity Ratio: NeuroSense Therapeutics Ltd. (NRSN)
The NeuroSense Therapeutics (NRSN) price chart reflects the dynamics of a company developing comprehensive ALS therapies to inhibit neuronal decay. The indicator stands at 0.00. However, the business's Israeli origin creates risks of trial disruptions and logistical failures due to local wars. Meanwhile, drug development follows an autonomous path, remaining independent of market inflation or central bank rate fluctuations.
NeuroSense Therapeutics, Ltd. (NRSN) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity NeuroSense Therapeutics|NRSN - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital NeuroSense Therapeutics|NRSN - Company Cumulative Debt|Debt to Book Value NeuroSense Therapeutics Ltd|NRSN - Company Long-Term Debts|Company Short-Term Debt NeuroSense Therapeutics|Quick Liquidity neurosense-tx.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:NeuroSense Therapeutics Ltd. NRSN
NeuroSense Therapeutics (NRSN) is investing in screening robotics and software data automation, which requires precise liquidity management to cover operating expenses. The current ratio of short-term loans to equity measures the proportion of liabilities with a maturity of over one year relative to equity, determining the risk of cash flow gaps. A decrease in this ratio confirms financial stability, whereas an increase signals an excessive debt load.
Analysis of competing companies
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|Short-Term Debt to Capital Ratio DNLI (denalitherapeutics.com)|Short-Term Debt to Capital HRMY|BHVN - Current Liabilities to Capital|Amylyx - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Trevi Corp TRVI|PRAX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital AVXL (anavex.com)|CeriBell (CBLL) - Short-Term Debt to Equity|Current Liabilities to Capital Prothena Biosciences (PRTA)|Short-Term Debt to Equity Alector Inc.|Annexon Biosciences Inc. (ANNX) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital OMER|NGNE - Current Liabilities to Capital|Short-Term Debt to Equity AC Immune SA ACIU|VYGR: Short-Term Debt to Capital Ratio|NMRA - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Scilex Holding Company, Inc. SCLX|TVGN: Short-Term Debt to Capital|Current Liabilities to Capital Alpha Cognition Inc. (ACOG)|Short-Term Debt to Equity Ratio CGTX|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio SAVA (Cassava)|Short-Term Loans to Capital Ratio ASRT|Short-Term Debt to Capital COYA (Coya Therapeutics)|Ratio of Short-Term Indebtedness to Capital VTGN|Ovid Rx - Short-Term Debt to Capital|Current Liabilities to Capital Acumen Pharmaceuticals Inc.|CervoMed Inc (CRVO) - Short-Term Debt to Equity|Alterity Therapeutics Limited - Ratio of Short-Term Indebtedness to Capital|CLNN (Clene Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital PepGen Corp|Short-Term Debt to Equity Jupiter Neurosciences (JUNS)|RLMD: Current Liabilities to Equity|Short-Term Debt to Capital ANVS (Annovis Bio Corp)|Grace Therapeutics Inc (GRCE) - Current Liabilities to Capital|AIFF: Short-Term Debt to Equity Ratio|KLTO - Short-Term Debt to Capital|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - Short-Term Debt to Equity Ratio|MTVA: Short-Term Loans to Capital Ratio|NRXS (NeurAxis, Inc) - Short-Term Debt to Capital|Helius Medical Technologies Inc. (HSDT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital PASG|Short-Term Debt to Equity Ratio bionomics.com.au NEUP|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|Short-Term Debt to Capital Coefficient Athira Pharma Inc (ATHA)|ADXN - Short-Term Debt to Equity|ALZN (Alzamend Neuro, Inc.) - Short-Term Debt to Capital Ratio|cyclerion.com (CYCN) - Short-Term Debt to Equity|Protagenic Therapeutics, Inc. - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Pasithea Therapeutics Corp|Cortigent Medical (CRGT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|CHRO: Short-Term Debt to Capital Ratio|Eliem - Short-Term Debt to Capital|Current Liabilities to Capital Intra-Cellular Therapies|LBPH (Longboard Pharma) - Short-Term Debt to Equity Ratio|Marinus Pharma (MRNS) - Short-Term Debt to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|NRBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX - Current Liabilities to Capital|Short-Term Debt to Equity Trevena, Inc TRVN|VIGL: Short-Term Debt to Capital Ratio|Anew Medical, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital cerevel.com